The Effect of Competing Direct-to-Consumer Advertising Campaigns on the Use of Drugs for Benign Prostatic Hyperplasia: Time Series Analysis

Journal of General Internal Medicine

Volumn 30, Issue 4, 2015, Pages 514-520

  Skeldon, Sean C ^a,b   Kozhimannil, Katy B ^c   Majumdar, Sumit R ^d   Law, Michael R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Advertising as topic; Benign prostatic hyperplasia; Health policy

Indexed keywords

DUTASTERIDE; SULFONAMIDE; TAMSULOSIN; URINARY TRACT AGENT;

DIRECT-TO-CONSUMER ADVERTIZING; EPIDEMIOLOGY; HUMAN; INAPPROPRIATE PRESCRIBING; MALE; PREVENTION AND CONTROL; PROCEDURES; PROSTATIC HYPERPLASIA; TRENDS; UNITED STATES;

DIRECT-TO-CONSUMER ADVERTISING; DUTASTERIDE; HUMANS; INAPPROPRIATE PRESCRIBING; INTERRUPTED TIME SERIES ANALYSIS; MALE; PROSTATIC HYPERPLASIA; SULFONAMIDES; UNITED STATES; UROLOGICAL AGENTS;

EID: 84937216219     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-014-3063-y     Document Type: Article

References (33)

1. Kornfield R, Donohue J, Berndt ER, Alexander GC. Promotion of prescription drugs to consumers and providers, 2001–2010. PLoS One 2013;8(3):e55504.
2. Wolfe SM. Direct-to-consumer advertising–education or emotion promotion? N Engl J Med 2002;346(7):524–6.
3. Stange KC. Time to ban direct-to-consumer prescription drug marketing. Ann Fam Med 2007;5(2):101–4.
4. Ross JS, Kravitz RL. Direct-to-Consumer Television Advertising: Time to Turn Off the Tube? J Gen Intern Med 2013;28(7):862–4.
5. Holmer AF. Direct-to-consumer advertising–strengthening our health care system. N Engl J Med 2002;346(7):526–8.
6. Mintzes B. Advertising of prescription-only medicines to the public: does evidence of benefit counterbalance harm? Annu Rev Public Health 2012;33:259–77.
7. Law MR, Majumdar SR, Soumerai SB. Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study. BMJ 2008;337(sep02 1):a1055.
8. Zachry WM III, Shepherd MD, Hinich MJ, Wilson JP, Brown CM, Lawson KA. Relationship between direct-to-consumer advertising and physician diagnosing and prescribing. Am J Health Syst Pharm 2002;59(1):42–9.
9. Dorn SD, Farley JF, Hansen RA, Shah ND, Sandler RS. Direct-to-consumer and physician promotion of tegaserod correlated with physician visits, diagnoses, and prescriptions. Gastroenterology 2009;137(2):518–24, 524.e1–2.
10. ’t Jong GW, Stricker BHC, Sturkenboom MCJM. Marketing in the lay media and prescriptions of terbinafine in primary care: Dutch cohort study. BMJ 2004;328(7445):931.
11. Law MR, Soumerai SB, Adams AS, Majumdar SR. Costs and consequences of direct-to-consumer advertising for clopidogrel in Medicaid. Arch Intern Med 2009;169(21):1969–74.
12. Hansen RA, Shaheen NJ, Schommer JC. Factors influencing the shift of patients from one proton pump inhibitor to another: the effect of direct-to-consumer advertising. Clin Ther 2005;27(9):1478–87.
13. Abrams P. New words for old: lower urinary tract symptoms for “prostatism”. BMJ 1994;308(6934):929–30.
14. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993;150(1):85–9.
15. Kupelian V, Wei JT, O’Leary MP, et al. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med 2006;166(21):2381–7.
16. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003;170(2 Pt 1):530–47.
17. Vaughan ED. Medical management of benign prostatic hyperplasia–are two drugs better than one? N Engl J Med 2003;349(25):2449–51.
18. Roehrborn CG, Schwinn DA. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 2004;171(3):1029–35.
19. Lowe FC. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther 2004;26(11):1701–13.
20. Nickel JC. Comparison of clinical trials with finasteride and dutasteride. Rev Urol 2004;6 Suppl 9:S31–9.
21. Abel GA, Chen K, Taback N, Hassett MJ, Schrag D, Weeks JC. Impact of oncology-related direct-to-consumer advertising: association with appropriate and inappropriate prescriptions. Cancer 2013;119(5):1065–72.
22. Ad$pender™ | Kantar Media [Internet]. [cited 2013 Jul 29]; Available from: http://kantarmediana.com/intelligence/products/adspender
23. Fox S. Health Information Online. Washington, D.C.: 2005.
24. Fox S. Online Health Search 2006. Washington, D.C.: 2006.
25. Nielsen NetRatings Search Engine Ratings - Search Engine Watch [Internet]. [cited 2013 Jul 29]; Available from: http://searchenginewatch.com/article/2067079/Nielsen-NetRatings-Search-Engine-Ratings
26. Google Trends [Internet]. [cited 2013 Jul 29]; Available from: http://www.google.com/trends/explore#cmpt=q
27. IMS National Prescription Audit™, January 2003–December 2007, IMS Health Incorporated.
28. Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women’s Health Initiative. JAMA 2004;292(16):1983–8.
29. Jackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, Krumholz HM. Use of fibrates in the United States and Canada. JAMA 2011;305(12):1217–24.
30. Wagner A K, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002;27(4):299–309.
31. U.S. Census Bureau DID. Population Estimates [Internet]. [cited 2013 Jul 29]; Available from: http://www.census.gov/popest/data/intercensal/national/nat2010.html
32. Kravitz RL, Epstein RM, Feldman MD, et al. Influence of patients’ requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA 2005;293(16):1995–2002.
33. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349(25):2387–98.